Dermata Therapeutics Inc (NASDAQ: DRMA) stock was trading higher Friday after the company announced the issuance of a new patent in Japan for its DMT410 program for hyperhidrosis (excessive sweating that’s not always related to heat or exercise). The patent, entitled “Compositions for the treatment of skin conditions” (Japanese Patent No. 7395576), further strengthens Dermata’s intellectual property for DMT410 for hyperhidrosis and could lead to further protections for additional indications. “We believe this patent issuance further validates DMT410’s novel concept to easily deliver botulinum …